Freitag Julien, Wickham James, Shah Kiran, Tenen Abi
Charles Sturt University, School of Biomedical Sciences, Orange, NSW, Australia.
Magellan Stem Cells, Box Hill, Victoria, Australia.
Future Sci OA. 2020 May 12;6(6):FSO584. doi: 10.2144/fsoa-2020-0048.
Acute respiratory distress syndrome (ARDS) is a condition of acute respiratory failure resulting from noncardiogenic pulmonary edema. It may occur as a consequence of lung infection, sepsis, trauma, aspiration or drug reaction. The pathogenesis of ARDS is understood to be an unregulated inflammatory cascade with both endothelial and epithelial layer damage leading to alveolar fluid collection and pulmonary edema. Despite improved understanding of the cause of ARDS, treatment remains supportive with a mortality rate ranging from 25-40%. Preclinical and early phase clinical trials have highlighted the potential role of mesenchymal stem cells in combating the inflammatory cascade through immunomodulatory mechanisms and assisting in tissue repair.
急性呼吸窘迫综合征（ARDS）是一种由非心源性肺水肿导致的急性呼吸衰竭病症。它可能因肺部感染、脓毒症、创伤、误吸或药物反应而发生。ARDS的发病机制被认为是一种不受调控的炎症级联反应，伴有内皮和上皮层损伤，导致肺泡积液和肺水肿。尽管对ARDS病因的认识有所提高，但治疗仍以支持性治疗为主，死亡率在25%至40%之间。临床前和早期临床试验突出了间充质干细胞通过免疫调节机制对抗炎症级联反应和协助组织修复的潜在作用。
